Global Diabetic Retinopathy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Diabetic Retinopathy Market Analysis

In recent years, the diabetic retinopathy market is anticipated to grow rapidly during the forecast period. Diabetic retinopathy (DR) is the most common cause of visual loss worldwide. The duration of hyperglycemia, diabetes and hypertension are the most clinically important risk factors for vision loss progression. Controlling blood sugar and blood pressure has been demonstrated to help prevent vision loss due to diabetic retinopathy. According to the International Diabetes Federation (IDF), the global prevalence of diabetes mellitus (DM) was around 27% from 2015 to 2019. The lowest rates were found in Europe (20.6%) and Southeast Asia (12.5%), while the most significant rates were found in Africa (33.8%), the Middle East and North Africa (33.8%), and the Western Pacific region (36.2%).

Global Diabetic Retinopathy Market Size

Global diabetic retinopathy market size was valued at USD 8.43 billion in 2024 and is projected to reach USD 16.19 billion by 2032, with a CAGR of 8.50% during the forecast period of 2025 to 2032.

Report Scope and Market Segmentation       

Diabetic Retinopathy Market Definition

Diabetes mellitus damages the blood vessels in the retina, resulting in diabetic retinopathy (DR). There are two types of diabetic retinopathy: non-proliferative and proliferative or progressed diabetic retinopathy. It is caused by changes in blood glucose levels, which cause abnormal growth of the light-sensitive structures in the eye. Dark patches or floating strings in the vision field, hazy or fluctuating vision, decreased colour vision, or vision loss are all symptoms of diabetic retinopathy.

Diabetic Retinopathy Market Dynamics

Drivers

• Increasing prevalence of diabetes

The rising prevalence of diabetes is a primary driver of the diabetic retinopathy market's growth. Along with this, the rising cases of blindness due to diabetes will further influence the market dynamics during the forecast period.   

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of diabetic retinopathy market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the diabetic retinopathy market. Additionally, high disposable income and favourable reimbursement scenario will result in the expansion of diabetic retinopathy market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the diabetic retinopathy market growth. Along with this, rising approvals and launches of new diabetic retinopathy drugs will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the diabetic retinopathy market growth during the forecast period.

Restraints/Challenges 

On the other hand, the high cost associated with the treatment of diabetic retinopathy will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the diabetic retinopathy market. Additionally, a decline in clinical visits due to COVID-19 outbreak and post-surgical complications will act as restrain and further impede the growth rate of market during the forecast period of 2025-2032.

This diabetic retinopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic retinopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Diabetic Retinopathy Market Scope

The diabetic retinopathy market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Treatment

• Medication
• Device
• Surgery
• Others

Diagnosis

• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Route of Administration

• Oral
• Intravitreal Injections
• Intravitreal Implants
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Diabetic Retinopathy Market Regional Analysis

The diabetic retinopathy market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Diabetic retinopathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the diabetic retinopathy market because of the growing prevalence of diabetic retinopathy and the presence of refined healthcare expenditure in this region. Additionally, growing focus of major key players on novel technology will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2025 to 2032 due to the population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Diabetic Retinopathy Market Share

The Diabetic retinopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetic retinopathy market.

Diabetic Retinopathy Market Leaders Operating in the Market Are:

• LEO Pharma A/S (Denmark)
• Amneal Pharmaceuticals LLC. (US)
• Glenmark Pharmaceuticals Limited (India)
• Dr. 'Reddy's Laboratories Ltd. (India)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Bausch Health Companies Inc. (Canada)
• Eli Lilly and Company (US)
• AbbVie Inc. (US)
• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Allergan (Ireland)
• Merck & Co., Inc. (US)
• IRIDEX Corporation (US)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)

Latest Developments in Diabetic Retinopathy Market

• In August 2020, Eyenuk had announced the U.S. Food and Drug Administration (FDA) approval for EyeArt Autonomous AI System for diabetic retinopathy screening. EyeArt is designed to help healthcare providers detect more than moderate diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in the eyes of adults with diabetes who have never been diagnosed with more than mild diabetic retinopathy

SKU-53232